Biogen | BIIB - Zysk Z Działalności Operacyjnej





Zysk Z Działalności Operacyjnej Zmiana Data
AbbVie USD 4.73B 1.08B 2026-03
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
Amgen USD 3.96B 464M 2025-12
Bayer EUR 1.11B 1.65B 2025-12
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Incyte USD 383.88M 47.43M 2025-12
Merck USD 6.24B 318M 2025-12
Moderna USD -857M 597M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD 4.24B 171M 2026-03
Pfizer USD 4.65B 3.99B 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 1.94B 239M 2026-03
Sanofi EUR 1.5B 2.29B 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Teva Pharmaceutical Industries USD 758M 271M 2026-03
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12